钠-葡萄糖协同转运蛋白2抑制剂在腹膜透析中作用的研究进展

Research progress on the role of sodium-glucose cotransporter 2 inhibitors in peritoneal dialysis

钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂是近年来临床应用较为广泛的一种新型降糖药物,主要通过抑制表达于肾脏近曲小管处的SGLT2来阻止肾脏对葡萄糖的重吸收,从而通过排出糖尿来降低血糖。除降糖作用外,SGLT2抑制剂同时有心血管保护、抑制炎症和氧化应激、改善肾脏疾病预后等多种作用。研究发现SGLT2在人腹膜间皮细胞中表达,并可能参与腹膜透析相关性腹膜纤维化和超滤衰竭的发生和发展,推测抑制SGLT2可能会抑制腹膜纤维化和改善超滤衰竭。因此,SGLT2抑制剂有望成为一种新的抗腹膜纤维化及改善超滤衰竭药物。本文就SGLT2抑制剂在腹膜透析中的研究进展作一综述,旨在探讨SGLT2抑制剂在改善腹膜纤维化和超滤衰竭中的作用机制,为防止腹膜透析相关并发症提供新的治疗方向。

Sodium-glucose cotransporter 2(SGLT2)inhibitors is a novel antidiabetic drug widely used in clinics in recent years,which is mainly expressed at the proximal convoluted tubules of the kidney to prevent the reabsorption of glucose by the kidney,thereby lowering blood glucose by excreting diabetes.Besides the hypoglycemic effect,SGLT2 inhibitors has many effects,such as cardiovascular protection,inhibition of inflammation and oxidative stress,and improvement of renal disease prognosis.Studies have found that SGLT2 is expressed in human peritoneal mesothelial cells and may be involved in the initiation and development of peritoneal dialysis-related peritoneal fibrosis and ultrafiltration failure.It is speculated that inhibition of SGLT2 may inhibit peritoneal fibrosis and improve ultrafiltration failure.Therefore,SGLT2 inhibitors may become a new anti-peritoneal fibrosis drug and improve ultrafiltration failure.This article reviews the progress of SGLT2 inhibitors in peritoneal dialysis,in order to explore the mechanism of SGLT2 inhibitors in improving peritoneal fibrosis and ultrafiltration failure,to provide a new therapeutic direction for preventing peritoneal dialysis-related complications.